Omeros Corp
Pharmaceuticals
Omeros Corp (OMER) Stock News
The latest OMER headlines and market coverage — 2 recent stories, updated throughout the day.
- GlobeNewswire Inc.·
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
Pomerantz LLP is investigating potential securities fraud claims against Omeros Corporation following the company's announcement on June 26, 2026, that the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a negative opinion on the marketing authorization application for narsoplimab for treating TA-TMA. The negative regulatory decision triggered a 19.12% stock price decline, falling $2.05 per share to $8.67.
- GlobeNewswire Inc.·
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Omeros Corporation - OMER
Pomerantz LLP is investigating potential securities fraud claims against Omeros Corporation following the company's announcement of a negative opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use on its marketing authorization application for narsoplimab. The news triggered a 19.12% stock price decline on June 26, 2026.